This paper aims to identify how many young adults on antihypertensive treatment have been misclassified as hypertensive. We identified subjects aged under 35 on antihypertensive treatment, from the Health Surveys for England, 1998England, -2004. Pretreatment systolic and diastolic blood pressures were calculated by adjusting on-treatment blood pressures for the effects of treatment. Treatment effects were derived from meta-analysis. Subjects were classified as hypertensive if pretreatment blood pressure was X160/100 mm Hg, or was X140/90 mm Hg in conjunction with high cardiovascular risk. We then identified the proportion of treated subjects on antihypertensive treatment who were truly eligible for treatment. 
was 164/100 mm Hg in those eligible for treatment, and 136/79 mm Hg in those not eligible. The analysis indicated that 29.2% of adults aged 16-34 (95% confidence interval (CI): 18.6-41.8%) were truly eligible for antihypertensive treatment: 32.0% (95% CI: 14.9-53.5%) of men and 25.0% (95% CI: 12.7-41.2%) of women. A total of 73.7% (14 of 19) of subjects eligible and 41.3% (19 of 46) of subjects not eligible for treatment either had a body mass index430 kg m À2 or kidney disease (v
Introduction
When blood pressure measurement is carried out in healthy adults, it is a type of diagnostic test. Individuals are classified either as hypertensive (eligible for antihypertensive treatment) or normotensive. Because of biological variation in blood pressure, like any diagnostic test, blood pressure measurement is subject to misclassification. Those diagnosed as hypertensive therefore include hypertensive individuals correctly identified as hypertensive (true positives), and normotensive individuals who have been misclassified (false positives). If the prevalence of hypertension in a population is low, false positives may be more common than true positives. Modelling suggests that this may be the case in adults under 35. If a diagnosis of hypertension is based on the average of three blood pressure measurements in adults aged 16-35, we would expect 31% (95% confidence interval (CI) 16-46%) of men on antihypertensives and 26% (95% CI 7-46%) of women on antihypertensives to be true hypertensives. 1 This means that adults under 35 who have been identified as hypertensive, are more likely to be false positives than to be truly hypertensive. This paper investigates the hypothesis that many young adults on antihypertensive treatment have been misclassified. It does so by identifying a population of young adults on antihypertensive treatment, estimating their likely pretreatment blood pressure and determining the proportion that would have been hypertensive pretreatment.
Materials and methods
Adults under 35 on antihypertensive treatment were identified from the Health Surveys for England conducted in the seven years from 1998 to 2004. In the surveys, blood pressure was measured in the right arm with the patient seated and at rest for five minutes. Three measurements were taken using an automated blood pressure monitor. In 2003, the equipment was changed from Dinamap to Omron. Subsequent blood pressure variables were derived initially using the Omron measurements, and then a calibration factor was used in the Health Survey for England to convert the readings to a Dinamap equivalent. The valid blood pressure was defined as the average of the second and third measurements. Readings where the subject had eaten, drunk or exercised in the previous half hour were categorized as invalid. Each individual's age and sex, their average valid systolic and diastolic blood pressure, and the antihypertensive treatments they were taking were identified from the survey. Data were copied into an Excel spreadsheet.
The effects of antihypertensive treatment on blood pressure were determined from a large meta-analysis. 3 At standard doses, in a subject whose blood pressure is 154/97 mm Hg, thiazide diuretics reduce blood pressure by 8. Pretreatment systolic and diastolic blood pressures were calculated deterministically, using these formulae to determine the effects of any antihypertensive treatment the subject was taking, and by increasing on-treatment blood pressures by this amount. Pretreatment blood pressure was used to calculate 10-year cardiovascular disease (CVD) risk. All calculations were carried out in Excel. Subjects were classified as hypertensive if their pretreatment blood pressure was X160/100 mm Hg, or if pretreatment blood pressure was X140/90 mm Hg in conjunction with a diagnosis of kidney disease, CVD or diabetes, or a pretreatment 10-year CVD risk X20%. 4 The proportion of treated subjects who were truly hypertensive was calculated for men and women, and compared to the positive predictive values reported in previous analysis. 1 All 95% CIs were calculated by the exact binomial method using EpiInfo 6.0 software.
Sensitivity analysis
Treatment effects. If we have underestimated the effects of antihypertensive treatment, subjects' pretreatment blood pressures would be higher and more treated subjects would be true hypertensives.
A sensitivity analysis investigated the extent to which our results were affected by changing assumptions about the effects of treatment. For the baseline analysis, it was assumed that subjects were taking standard doses of antihypertensives. The analysis was repeated with the assumption that all subjects were taking high-dose antihypertensives (for example, bendroflumethiazide 5 mg).
Could effects of antihypertensive treatment be much greater in young adults? There is some evidence that calcium channel blockers may be more effective and angiotensin converting enzyme (ACE) inhibitors less effective in older subjects, but there is little conclusive evidence for those under 35. [5] [6] [7] We repeated the analysis with the assumption that the effect of treatment in young adults was 50% greater than estimated from meta-analysis. 3 Does the assumption that the effects of treatment are the same on all individuals affect the results? We allowed for random variation in the treatment effect by incorporating an error term with a coefficient of variation (CV) of 0.300. This means that if the calculated effect of treatment in an individual is 10 mm Hg, their treatment effect in the model will be randomly selected from a distribution with a mean of 10 mm Hg and a 95% CI of 6 mm Hg.
Probabilistic modelling of pretreatment blood pressure. When we determine a subject's likely pretreatment blood pressure, it is also subject to variation and possible misclassification. Pretreatment blood pressure is equal to on-treatment blood pressure minus the treatment effect. On-treatment blood pressure is subject to within-individual variation, and the treatment effect is subject to between-individual variation. The standard deviation of pretreatment blood pressure (S pre ) is therefore the square root of the sum of the standard deviation of on-treatment blood pressure (S post ) squared and the treatment effect (
. A further sensitivity analysis was carried out to determine an individual probability of being hypertensive for each subject. The average of these probabilities is the average probability of all treated patients being above the treatment thresholds and therefore truly hypertensive. This analysis was undertaken as follows. The following blood pressure treatment thresholds were determined for each subject: 140/90 mm Hg for those with kidney disease, CVD or diabetes, and 160/100 mm Hg for all others. Each subject's calculated pretreatment blood pressure was treated as an estimate of their mean pretreatment blood pressure and their pretreatment blood pressures were assumed to be normally distributed. From the mean and standard deviation of each subject's pretreatment blood pressure, was derived the probability of obtaining a reading below the treatment threshold.
The standard deviation of on-treatment blood pressure (S post ) was determined from the product of on-treatment blood pressure and the CV for within-individual variation in blood pressure [standard deviation ¼ CV) Â (mean)]. Systolic blood pressure has a between-visit CV of 9.9% and diastolic blood pressure has a between-visit CV of 9.2%, when blood pressure at each visit is based on the mean of two or three measurements with a random zero sphygmomanometer. 8 There are no published data on the betweenindividual standard deviation of the effects of treatment. Therefore, two estimates were used reflecting the full range of possible variation in treatment effects. For one estimate the standard deviation of the treatment effect is derived from the 95% CIs and sample sizes quoted in meta-analysis. 3 This gives a large estimate of within-individual variation because some (if not all) of the apparent variation in treatment effect between individuals can be explained by within-individual variation in pretreatment and on-treatment blood pressure. 9 For the other estimate, the standard deviation of the treatment effect was assumed to be zero. This reflects an assumption that there is no variation in treatment effect between individuals with the same pretreatment blood pressure.
Over-dispersion of health survey blood pressures. The blood pressures recorded in the health surveys are the starting point for this analysis. However, these recorded blood pressures include a degree of within-individual variation. This means that the recorded blood pressures derived from the health survey blood pressures are more widely dispersed than they should be. It would be strictly more accurate to take account of this withinindividual variation by adjusting the recorded blood pressures, to remove the effects of over-dispersion. This has not been done, for several reasons. First, because the effect of undertaking this further adjustment would be to reduce all those blood pressures that are above the mean, decreasing the numbers eligible for treatment and strengthening the findings of the paper. Second, because undertaking this adjustment requires further assumptions to be made about the variability of home blood pressure measurements which are hard to justify empirically.
Third, because the variability of the health survey blood pressures-based on measurements at a single home visit-may in fact be little different to variability of blood pressures based on the average of measurements by a clinician at two clinic visits. Treatment decisions are normally made after two clinic-based blood pressure measurements. Published evidence suggests that measurements at home are likely to show less variability than measurements in a clinic. 10 Systolic blood pressure measured at one clinic visit is 1.4 times and diastolic blood pressure 1.1 times more variable than measurement at one home visit. The CV of measurement at one clinic visit is 1.4 (that is, O2) times greater than the average of measurements at two clinic visits. Therefore, blood pressure variability at one home visit is in fact very similar to variability of blood pressure at two clinic visits meaning that the adjustments required are in fact likely to be small.
Results
From the health surveys, 76 subjects aged 16-34 were identified as taking drugs prescribed for hypertension of these 65 (85.5%; 25 men and 40 women) had a valid blood pressure ( Table 1 ). The prevalence of antihypertensive treatment was similar across all 7 years of the survey. The deterministic analysis identified 19 adults on antihypertensive therapy aged 16-34 as truly eligible for antihypertensive treatment (29.2%; 95% CI: 18.6-41.8%): 32.0% (95% CI: 14.9-53.5%) of men and 27.5% (95% CI: 14.6-43.9%) of women ( Table 2) .
The numbers taking diuretics (21), b-blockers (28), ACE inhibitors (22) and calcium blockers (21) were similar, with three subjects taking other drugs. Forty-two subjects were taking one antihypertensive drug, 16 were taking two drugs and seven were taking three drugs. Average pretreatment blood pressure was 144/85 mm Hg, 164/100 mm Hg in those eligible for treatment and 136/79 mm Hg in those not eligible (Table 3) . Overall, 20.7% of those taking one or two drugs and 100% of those taking With the assumption that treatment effects in young adults are 50% greater than estimated from meta-analysis, the proportion of treated men under 35 truly eligible for antihypertensive treatment increased to 52.0% (95% CI: 31.3-72.2%), and the proportion of treated women to 40.0% (95% CI: 24.9-56.7%). However this still implies that half of young adults on antihypertensives have been misdiagnosed. Allowing for a degree of between-individual variation in the treatment effect has little effect on the number of subjects misclassified.
Probabilistic modelling of pretreatment blood pressure. The between-individual CV in treatment effect derived from meta-analysis is 1.76 for systolic and 1.75 for diastolic blood pressure. This is a very large estimate of variation in response to treatment. Using this estimate the average probability of being above the treatment threshold is 33.1% (28.8% for women and 40.0% for men). Under the second assumption, the between-individual CV in treatment effect is zero for both systolic and diastolic blood pressure. Using this estimate the average probability of being below the treatment threshold is 31.8% (27.0% for women and 3.96% for men). Under either assumption the probability of being eligible for treatment is essentially the same as with deterministic modelling.
Discussion
A previous paper predicted that if a random sample of adults aged 16-34 had their blood pressure measured three times, only 31% of men and 26% women who were diagnosed as hypertensive would be truly eligible for treatment. 1 This analysis found that 32% of men and 25% of women aged 16-34, who are on antihypertensive drugs, were truly eligible for treatment, almost exactly as predicted. The results are robust to a wide range of assumptions about treatment effects, and the results of probabilistic modelling are the same. Because blood pressures in young men are higher than those in young women, we would expect to find a higher proportion of young men to be on treatment. However, we found more young women than young men on treatment. This may simply reflect the fact that young women consult more than twice as frequently as young men, and therefore are more likely to have their blood pressure measured than young men.
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Although the sample size in this analysis is small, it is drawn from a representative sample of the population. While a larger sample of young adults on antihypertensives might be obtained from a specialist clinic, such individuals are unlikely to be representative of all young adults on antihypertensives.
Compliance with antihypertensive medication in clinical practice is imperfect and compliance may be lower in young men and those without CVD. 12 If we take account of imperfect compliance, the effects of treatment may be less than modelled here, pretreatment blood pressures lower and hence the extent of misclassification greater.
The findings support the hypothesis that most young adults on antihypertensive treatment have been misdiagnosed. Applying the prevalence of treated subjects from the Health Survey for England, 2003 to the population of England in 2005, we find that currently 38 300 persons in England aged 16-34 are on antihypertensive drugs.
2 This paper suggests that 27 300 of these have been misdiagnosed. Those young, adult hypertensives who have been correctly diagnosed, are almost always overweight and the majority are clinically obese.
Is this misdiagnosis important? Lower blood pressure is associated with a lower risk of CVD even at least down to 115/75 mm Hg. 13 Reducing blood pressure probably reduces the risk of CVD even in those whose blood pressure is not elevated. However average 10-year cardiovascular risk is invariably below 5% in young adults; therefore, the absolute benefits of treatment are very small. Many subjects are unlikely to judge the benefits of treatment worthwhile.
14 Is there a solution to this problem? CVD prevention through antihypertensive treatment is hard to justify in young adults. So why do we measure their blood pressure? Could it be to detect accelerated hypertension? Accelerated hypertension is rare, with an annual incidence in England reported as 1-2 per 100 000. 15 Furthermore, patients with accelerated hypertension who present to hospital have diastolic blood pressures of at least 120 mm Hg. 16 High blood pressure in young adults appears to be largely a characteristic associated with obesity.
The evidence from this study suggests that misdiagnosis of hypertension in young adults is a real phenomenon. This problem arises because eligibility for treatment in this age group is defined by a single blood pressure threshold. Yet, estimated cardiovascular risk rather than a blood pressure threshold identifies those who benefit most from treatment. Misdiagnosis is inevitable when an imperfect screening test with an arbitrary diagnostic threshold is used in a population unlikely to benefit from treatment.
What is known about the topic? K Measured blood pressure shows substantial day to day variation. Because of this there is a finite probability that a subject will be misdiagnosed as hypertensive. K Hypertension has a low prevalence in adults under 35. It has been demonstrated that in adults under 35, following current British guidelines for blood pressure measurement and diagnosis could misdiagnose normal blood pressure more commonly than diagnose hypertension.
What this study adds K Only 29% of adults under 35 in the Health Survey for England who were on antihypertensive treatment were hypertensive before treatment K These results are consistent with the hypothesis that most young adults currently on antihypertensives are treated as a result of misclassification K Of 38 300 young adults currently on antihypertensive treatment in England 27 300 have been treated as a result of misclassification
Estimating the proportion of correct diagnosis T Marshall et al
In meta-analysis, the average reduction in blood pressure was 8.8 mm Hg systolic and 4.4 mm Hg diastolic at standard dose of a thiazide (for example, bendroflumethiazide 2.5 mg). Drugs reduced blood pressure from all pretreatment levels, more so from higher levels; for a 10 mm Hg higher blood pressure, the reduction was 1.0 mm Hg systolic and 1.1 mm Hg diastolic greater. 3 Average pretreatment blood pressure in the meta-analysis was 154/97 mm Hg. The effect of a standard-dose thiazide on systolic blood pressure is therefore given as 8.8 þ 1.0 Â (pretreatment systolic BPÀ154)/10. The effect of a standard-dose thiazide on diastolic blood pressure is therefore given as 8.8 þ 1.1 Â (pretreatment systolic BPÀ97)/10. Therefore, the effects of a standarddose thiazide can be expressed as shown in Table A1 .
The effects of each class of drug at half-standard dose, standard dose and high dose are shown in Table A2 . 
